HI-Bio, A Biogen Company
5 clinical trials · Sponsor
◉ Watch HI-Bio, A Biogen Company
| Record | Firm | Date |
|---|---|---|
| A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old (NCT06064929) | HI-Bio, A Biogen Company | 2023-11-01 |
| A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers (NCT05928585) | HI-Bio, A Biogen Company | 2023-07-06 |
| Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy (NCT05065970) | HI-Bio, A Biogen Company | 2021-08-31 |
| Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) (NCT04733040) | HI-Bio, A Biogen Company | 2021-01-20 |
| Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NCT04145440) | HI-Bio, A Biogen Company | 2019-10-15 |
Track HI-Bio, A Biogen Company automatically
Every clearance here is in the API, with alerts when new ones post.